Editorial: The diversified role of mitochondria in cancer

Siyuan Song; Qingqing Xia; Yu'e Liu; Kuo Chen; Fengqian Chen; Jin Zhang; Yi Wang

doi:10.3389/fgene.2024.1494075

Editorial: The diversified role of mitochondria in cancer

Front Genet. 2024 Sep 27:15:1494075. doi: 10.3389/fgene.2024.1494075. eCollection 2024.

Authors

Siyuan Song^#¹, Qingqing Xia^#², Yu'e Liu^#³, Kuo Chen^#⁴, Fengqian Chen⁵, Jin Zhang⁶, Yi Wang^{7

8}

Affiliations

¹ Department of Neuroscience, Baylor College of Medicine, Houston, TX, United States.
² School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
³ Division of Hematology/Oncology, Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States.
⁴ First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
⁵ Cellphire Therapeutics Inc., Rockville, MD, United States.
⁶ Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, MS, United States.
⁷ Center of Critical Care Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
⁸ Clinical Immunology Translational Medicine Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, Chengdu, China.

^# Contributed equally.

No abstract available

Keywords: biomarkers; cancer metabolism; immune evasion; mitochondrial dysfunction; mitochondrial-targeted therapies; personalized therapy; programmed cell death; tumor microenvironment.

Publication types

Editorial

Grants and funding

The authors declare that financial support was received for the research, authorship, and/or publication of this article. This study is supported by the National Natural Science Foundation of China (81802504) and the Sichuan Science and Technology Program (2023YFH0010).